Patents Assigned to Ethypharm
  • Publication number: 20190125663
    Abstract: The present invention relates to granules of active ingredient with double taste masking, wherein the double taste masking is achieved by a hot-melt compound selected from waxes, hydrogenated vegetable oils, fatty acids, mono-, di- and triesters of fatty acids and of glycerol, triglycerides, glycerides, polyoxylglycerides, fatty alcohols, and mixtures thereof, and a thermoplastic polymer that is soluble at a pH less than or equal to 5. The invention also relates to the method for producing these granules and to orodispersible tablets containing these coated granules.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 2, 2019
    Applicant: Ethypharm
    Inventors: Catherine Herry, Caroline Ailhas
  • Patent number: 10258692
    Abstract: The present invention concerns an oral pharmaceutical formulation made from a microemulsion between an aqueous solution comprising at least one BCS (Biopharmaceutics Classification System) class III active principle and one oily phase comprising an oily vehicle that is self-emulsifiable on contact with water.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: April 16, 2019
    Assignee: ETHYPHARM
    Inventors: Caroline Ailhas, Catherine Herry
  • Patent number: 10111869
    Abstract: The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in table form suitable for reducing blood concentration fluctuations of said opioid.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: October 30, 2018
    Assignee: ETHYPHARM
    Inventors: Catherine Herry, Maryline Boyer, Francoise Vauzelle-Kervroedan, Pascal Oury
  • Patent number: 10111832
    Abstract: Embodiments of the present invention provide an orodispersible tablet having a hardness of 30 to 80 N, and preferably 40 to 75 N, a brittleness less than 1% and preferably less than 0.5%, disintegrating in the mouth within 60 seconds and preferably within 40 seconds, comprising an active ingredient in the form of coated microcrystals or microgranules and a mixture of excipients chosen from a group comprising a diluent, a disintegrant, a sweetener, a binder, a levelling agent, a humectant or wetting agent, a lubricant, a flavoring agent, a dye, and mixtures thereof, said mixture of excipients preferably coming in the form of grains.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: October 30, 2018
    Assignee: ETHYPHARM
    Inventors: Isabelle Decorte, Edouard Gendrot, Yann Prevost
  • Patent number: 9993431
    Abstract: The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: June 12, 2018
    Assignee: Ethypharm
    Inventor: Vincent Billoet
  • Patent number: 9877925
    Abstract: A sustained release oral pharmaceutical form suitable for single daily dose administration has a neutral microgranule coated with a mounting layer of active ingredient and pharmaceutically acceptable binder; and a coating layer of a hydrophobic coating polymer of a non-water soluble cellulose derivative, and at least 20% of inert load in relation to dry weight of hydrophobic coating polymer. The pharmaceutical form has improved resistance to rapid release of active ingredient, particularly in the presence of alcohol.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: January 30, 2018
    Assignee: ETHYPHARM
    Inventors: Catherine Herry, Laury Trichard
  • Patent number: 9629800
    Abstract: The present invention concerns gastroretentive formulation comprising an active substance granulated with a mixture of a weak gelling agent, a strong gelling agent, and a gas generating agent and process for manufacturing said formulation.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: April 25, 2017
    Assignee: ETHYPHARM
    Inventors: Mahendra Chaudhari, Omprakash D. Chandwani, Rajashree S. Yelegaonkar
  • Patent number: 9616071
    Abstract: An oral sustained release pharmaceutical composition comprising a plurality of granules having diameters of not more than 1000 ?m, wherein each of the granules comprise a nucleus granule comprised of beraprost sodium and a coating agent coating the nucleus granule, and wherein the coating agent is comprised of a first skin layer containing one or more relatively water-insoluble macromolecular substances, and a second skin layer containing one or more hot-melt low-melting substances.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: April 11, 2017
    Assignees: ETHYPHARM, TORAY INDUSTRIES, INC.
    Inventors: Sandrine Salle, Emmanuel Guerin
  • Patent number: 9603797
    Abstract: The present invention relates to an oral and/or buccal composition in the form of a thin film of a pharmaceutically active ingredient weakly soluble in water and gastro-intestinal tract fluids, comprising particles of said active ingredient dispersed in a film-forming polymer, at least 50% by weight of the total weight of the active ingredient having a particle size distribution such that at least 90% of said particles have a size below 1000 nm, preferably less than 800 nm, and even more preferably less than 600 nm, and to the method of preparing that composition and the use thereof.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: March 28, 2017
    Assignee: ETHYPHARM
    Inventors: Catherine Herry, Vincent Billoet, Pascal Oury
  • Publication number: 20170016925
    Abstract: A pharmaceutical form for combating chemical submission includes an active ingredient and at least one compound which enables immediate modification of the organoleptic characteristics of a beverage into which the pharmaceutical form is introduced. The compound is selected from the group consisting of an opacifier, a fluorescent agent, floating particles, particles that are perceptible in the mouth, effervescent microgranules, and mixtures thereof.
    Type: Application
    Filed: September 30, 2016
    Publication date: January 19, 2017
    Applicant: ETHYPHARM
    Inventors: CATHERINE HERRY, PAULINE CONTAMIN, EMMANUEL DUPAU
  • Patent number: 9492397
    Abstract: Oral pharmaceutical form containing microgranules for the sustained release of at least one active principle, including a neutral carrier that is insoluble in water or in an alcohol solution, or a neutral carrier rendered insoluble in water or an alcohol solution, comprising at least one first mounting layer containing at least one active principle and optionally a pharmaceutically acceptable binding agent, wherein the whole comprises at least one coating based on at least one hydrophobic polymer.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: November 15, 2016
    Assignee: ETHYPHARM
    Inventors: Catherine Herry, Laury Trichard-Trolet
  • Publication number: 20160310434
    Abstract: The invention relates to a pharmaceutical matrix tablet which can be administered orally once or twice per day with gastro-retentive controlled release of Baclofen.
    Type: Application
    Filed: December 18, 2014
    Publication date: October 27, 2016
    Applicant: ETHYPHARM
    Inventors: CATHERINE HERRY, PAULINE CONTAMIN
  • Patent number: 9446002
    Abstract: The invention relates to a directly-compressible gastro-resistant spheroid. The spheroid comprises: (i) a core containing one or more active substances; (ii) a flexible, deformable film which directly coats the aforementioned core and which comprises an enteric polymer and a mixture of saturated and/or unsaturated polyglycosylated glycerides, the fatty acids of which include at least 8 carbon atoms; and (iii) an outer water-dispersible layer containing at least one disintegrating agent. The invention further relates to multiparticular tablets comprising said spheroids.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: September 20, 2016
    Assignee: ETHYPHARM
    Inventors: Philippe Chenevier, Dominique Marechal
  • Publication number: 20150359735
    Abstract: The present invention relates to an oral and/or buccal composition in the form of a thin film of a pharmaceutically active ingredient weakly soluble in water and gastro-intestinal tract fluids, comprising particles of said active ingredient dispersed in a film-forming polymer, at least 50% by weight of the total weight of the active ingredient having a particle size distribution such that at least 90% of said particles have a size below 1000 nm, preferably less than 800 nm, and even more preferably less than 600 nm, and to the method of preparing that composition and the use thereof.
    Type: Application
    Filed: December 9, 2013
    Publication date: December 17, 2015
    Applicant: ETHYPHARM
    Inventors: Catherine HERRY, Vincent BILLOET, Pascal OURY
  • Publication number: 20150335581
    Abstract: Embodiments of the present invention provide an orodispersible tablet having a hardness of 30 to 80 N, and preferably 40 to 75 N, a brittleness less than 1% and preferably less than 0.5%, disintegrating in the mouth within 60 seconds and preferably within 40 seconds, comprising an active ingredient in the form of coated microcrystals or microgranules and a mixture of excipients chosen from a group comprising a diluent, a disintegrant, a sweetener, a binder, a levelling agent, a humectant or wetting agent, a lubricant, a flavouring agent, a dye, and mixtures thereof, said mixture of excipients preferably coming in the form of grains.
    Type: Application
    Filed: December 17, 2013
    Publication date: November 26, 2015
    Applicant: ETHYPHARM
    Inventors: Isabelle DECORTE, Edouard GENDROT, Yann PREVOST
  • Publication number: 20150246035
    Abstract: Water-insoluble matrix tablets which are capable of prolonged release of active principles liable to be diverted for drug addiction purposes, the said active principles being dispersed within a tabletting matrix composed of at least one excipient selected from the group consisting of pH-independent, water-insoluble delay polymers, inorganic excipients and mixtures thereof, and exhibiting a crush resistance of at least 4 MPa.
    Type: Application
    Filed: April 29, 2015
    Publication date: September 3, 2015
    Applicant: ETHYPHARM SA
    Inventors: Vincent CAILLY-DUFESTEL, Catherine HERRY, Johnatan BACON, Pascal OURY
  • Publication number: 20140322321
    Abstract: The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection.
    Type: Application
    Filed: December 6, 2012
    Publication date: October 30, 2014
    Applicant: ETHYPHARM
    Inventors: Catherine Herry, Pauline Contamin
  • Patent number: 8865219
    Abstract: The invention concerns coated granules including (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, the pharmacological active principle being complexed by low cation-exchange resin containing carboxylic acid groups (COO?), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of the components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: October 21, 2014
    Assignee: Ethypharm
    Inventors: Mahendra B. Chaudhari, Edouard Gendrot
  • Publication number: 20140255480
    Abstract: The invention relates to a pharmaceutical formulation of nanonised fenofibrate, to a method for preparing same, and to the uses thereof.
    Type: Application
    Filed: April 7, 2014
    Publication date: September 11, 2014
    Applicant: ETHYPHARM
    Inventors: Catherine HERRY, Pascal OURY
  • Patent number: 8815944
    Abstract: The present invention relates to an injectable pharmaceutical composition with gelling properties containing: -an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein the organogelling substance is chosen among L-tyrosine derivatives responding to the following formula (I) wherein: R1 is an alkyl group containing 1 to 3 carbon atoms, linear or branched; and R2 is a hydrophobic group chosen among aliphatic saturated or unsaturated fatty chains or aryl or arylalkyl groups. Its use as a vector for the release of active principles, as well as its process of preparation.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: August 26, 2014
    Assignees: Ethypharm, Universite de Montreal
    Inventors: Jean-Chrisophe Leroux, Guillaume Bastiat